Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Cost-effectiveness of testing for breast cancer susceptibility genes.

Holland ML, Huston A, Noyes K.

Value Health. 2009 Mar-Apr;12(2):207-16. doi: 10.1111/j.1524-4733.2008.00418.x. Epub 2008 Jul 18.

2.

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR.

Ann Intern Med. 2006 Mar 21;144(6):397-406.

PMID:
16549852
3.
4.

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI.

J Clin Oncol. 1998 Mar;16(3):979-85.

PMID:
9508180
5.

Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.

Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB.

Obstet Gynecol. 2013 Jan;121(1):14-24. doi: http://10.1097/AOG.0b013e3182783c2f.

PMID:
23232752
6.

Costs and benefits of diagnosing familial breast cancer.

Heimdal K, Maehle L, Møller P.

Dis Markers. 1999 Oct;15(1-3):167-73.

7.

Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.

Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI.

Cancer J Sci Am. 2000 Jan-Feb;6(1):13-20.

PMID:
10696733
8.

A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.

Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ.

Value Health. 2017 Apr;20(4):547-555. doi: 10.1016/j.jval.2017.01.006. Epub 2017 Feb 23.

PMID:
28407996
9.

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.

Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.

J Natl Cancer Inst. 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. Print 2015 Jan.

10.

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.

Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.

Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.

11.

Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.

Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA.

Med Decis Making. 1998 Oct-Dec;18(4):365-75.

PMID:
10372578
12.

Expanding the criteria for BRCA mutation testing in breast cancer survivors.

Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B.

J Clin Oncol. 2010 Sep 20;28(27):4214-20. doi: 10.1200/JCO.2010.28.0719. Epub 2010 Aug 23.

PMID:
20733129
13.

Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.

Norum J, Hagen AI, Maehle L, Apold J, Burn J, Møller P.

Eur J Cancer. 2008 May;44(7):963-71. doi: 10.1016/j.ejca.2008.02.025. Epub 2008 Mar 24.

PMID:
18362067
14.

Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.

Cott Chubiz JE, Lee JM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, McMahon PM, Ryan PD, Gazelle GS.

Cancer. 2013 Mar 15;119(6):1266-76. doi: 10.1002/cncr.27864. Epub 2012 Nov 26.

15.

Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.

Manchanda R, Legood R, Pearce L, Menon U.

Gynecol Oncol. 2015 Dec;139(3):487-94. doi: 10.1016/j.ygyno.2015.10.001. Epub 2015 Oct 5.

PMID:
26436478
16.

Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.

Schrag D, Kuntz KM, Garber JE, Weeks JC.

JAMA. 2000 Feb 2;283(5):617-24.

PMID:
10665701
17.

Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.

Schrag D, Kuntz KM, Garber JE, Weeks JC.

N Engl J Med. 1997 May 15;336(20):1465-71. Erratum in: N Engl J Med 1997 Aug 7;337(6):434.

18.
19.

Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.

Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans DG, Hopper JL, Macinnis RJ, Menon U, Jacobs I, Legood R.

Am J Obstet Gynecol. 2017 Nov;217(5):578.e1-578.e12. doi: 10.1016/j.ajog.2017.06.038. Epub 2017 Jul 6.

PMID:
28690137
20.

Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2.

Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI.

J Clin Oncol. 1999 Feb;17(2):494-500.

PMID:
10080590

Supplemental Content

Support Center